Survey of treatment recommendations for anaplastic oligodendroglioma
Memorial Sloan-Kettering Cancer Center, New York, NY, USA (L.E.A., A.B.L., L.M.D.); Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA (D.N.L.); Northwestern University, Evanston, IL, USA (N.P.); Northwestern University, Feinberg School of Medicine, Chicago, IL, USA (J.J.R.); Princess Margaret Hospital, Toronto, Canada (W.M.); Children's Hospital of Los Angeles, Los Angeles, CA, USA (J.F.); London Regional Cancer Centre, London, Canada (D.R.M.); and University of Calgary, Calgary, Canada (J.G.C.)
Address correspondence to Lauren E. Abrey, Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA (abreyl{at}mskcc.org).
 |
Abstract |
|---|
Anaplastic oligodendroglioma is a malignant brain tumor uniquely sensitive to treatment with both chemotherapy and radiotherapy. There are few prospective clinical trials for newly diagnosed patients and multiple approaches to the treatment of these patients. This study explored the recommended treatment offered by experts in neuro-oncology. A Web-based survey was developed and distributed to 800 members of the Society of Neuro-Oncology (SNO) who had an e-mail address listed with SNO. Questions addressed use of molecular genetic information and treatment recommendations. A total of 99 clinical SNO members (20%) responded. The majority reported practicing at an academic center in the United States. Two-thirds of respondents see more than five patients with newly diagnosed anaplastic oligodendroglioma annually. Molecular genetic testing was requested for more than 75% of patients, and the results significantly influenced treatment recommendations (p = 0.000003). Regardless of molecular genetic status, the most commonly recommended treatment was the use of concurrent temozolomide and radiotherapy followed by adjuvant temozolomide (18%-34%). The current survey demonstrates that although neuro-oncologists have embraced the use of molecular genetic studies in newly diagnosed anaplastic oligodendroglioma, treatment recommendations vary widely and are often independent of the molecular data.
Keywords: 1p, 19q, anaplastic oligodendroglioma, molecular genetic studies, radiotherapy, survey, temozolomide, treatment recommendations
Received April 27, 2006; Accepted November 8, 2006
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. M. DeAngelis Anaplastic Gliomas J. Clin. Oncol., December 10, 2009; 27(35): 5861 - 5862. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Snuderl, A. F. Eichler, K. L. Ligon, Q. U. Vu, M. Silver, R. A. Betensky, A. H. Ligon, P. Y. Wen, D. N. Louis, and A. J. Iafrate Polysomy for Chromosomes 1 and 19 Predicts Earlier Recurrence in Anaplastic Oligodendrogliomas with Concurrent 1p/19q Loss Clin. Cancer Res., October 15, 2009; 15(20): 6430 - 6437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mahajan and R. A. Prayson Repeated Molecular Testing in Gliomas: A Retrospective Study of 53 Cases Am J Clin Pathol, July 1, 2009; 132(1): 118 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Vogelbaum, B. Berkey, D. Peereboom, D. Macdonald, C. Giannini, J. H. Suh, R. Jenkins, J. Herman, P. Brown, D. T. Blumenthal, et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131 Neuro Oncology, April 1, 2009; 11(2): 167 - 175. [Abstract] [Full Text] [PDF]
|
|